搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
The Pharma Letter
2 天
Positive Phase III trials results with BMS’ Sotyktu
US pharma major Bristol Myers Squibb has announced positive results from POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055 ...
The Pharma Letter
2 天
AstraZeneca withdraws EU submission for lung cancer drug
AstraZeneca and Daiichi Sankyo withdraw EU application for datopotamab deruxtecan in NSCLC after Phase III trial shows no ...
The Pharma Letter
2 天
Viatris faces FDA import restrictions at Indian facility
Viatris faces US FDA regulatory action on its Indore, India facility, with a warning letter and import alert restricting 11 ...
The Pharma Letter
2 天
FDA approves first generic of Victoza
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza ...
The Pharma Letter
2 天
Sumitomo gains FDA approval of Gemtesa for OAB
The US subsidiary of Japan’s Sumitomo Pharma announced that the US Food and Drug Administration (FDA) has approved Gemtesa ...
The Pharma Letter
2 天
RAPT obtains worldwide rights ex-China to Jemincare MAb
USA-based immunology company RAPT Therapeutics has entered into an exclusive license agreement with Shanghai Jemincare ...
The Pharma Letter
3 天
FDA nod for Rhythm Pharma’s Imcivree
The US Food and Drug Administration (FDA) on Friday approved an expanded indication for Imcivree (setmelanotide), from Boston ...
The Pharma Letter
2 天
Traws Pharma soars as it advances H5N1 bird flu treatment
USA-based clinical-stage biopharma Traws Pharma saw its shares leap more than 150% to $12.57 as it announced progress in the ...
The Pharma Letter
2 天
Aficamten attracts more interest as Sanofi buys China rights
Cytokinetics (Nasdaq: CYTK) has sold Sanofi (Euronext: SAN) exclusive rights to develop and commercialize aficamten in China.
The Pharma Letter
3 天
Shionogi to acquire full ownership of joint ventures with Ping An
Shionogi to acquire full ownership of its joint ventures with Ping An subsidiaries, dissolving partnerships to refocus on ...
The Pharma Letter
3 天
Grifols’ Albutein misses primary Phase III endpoint
Spanish plasma-based medicines maker Grifols has announced disappointing top-line data from its Phase III PRECIOSA clinical ...
The Pharma Letter
3 天
Another bump in the road for XBiotech and bermekimab
XBiotech halts rheumatology program after Phase II trial failure for rheumatoid arthritis, citing data irregularities and ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈